WorldCat Identities

Milanowski, Janusz

Overview
Works: 20 works in 20 publications in 2 languages and 29 library holdings
Roles: Other, Contributor
Publication Timeline
.
Most widely held works by Janusz Milanowski
Polymorphisms of Genes Encoding Multidrug Resistance Proteins as a Predictive Factor for Second-Line Docetaxel Therapy in Advanced Non-small Cell Lung Cancer by Michał Szczyrek( )

1 edition published in 2016 in English and held by 2 WorldCat member libraries worldwide

Bronchial carcinoid in a 39-year-old man treated for bronchial asthma: a case report by Justyna Emeryk( )

1 edition published in 2008 in English and held by 2 WorldCat member libraries worldwide

Prevalence of NRAS, PTEN and AKT1 gene mutations in the central nervous system metastases of non-small cell lung cancer by Marcin Nicoś( )

1 edition published in 2017 in English and held by 2 WorldCat member libraries worldwide

Middle age enhances expression of innate immunity genes in a female mouse model of pulmonary fibrosis by Marcin Golec( )

1 edition published in 2017 in English and held by 2 WorldCat member libraries worldwide

Evaluation of miR-506 and miR-4316 expression in early and non-invasive diagnosis of colorectal cancer by Paweł Krawczyk( )

1 edition published in 2017 in English and held by 2 WorldCat member libraries worldwide

Analysis of KRAS and BRAF genes mutation in the central nervous system metastases of non-small cell lung cancer by Marcin Nicoś( )

1 edition published in 2015 in English and held by 2 WorldCat member libraries worldwide

Palenie tytoniu : wpływ na zdrowie i program walki z nałogiem( Book )

1 edition published in 2001 in Polish and held by 2 WorldCat member libraries worldwide

Application of plasma circulating microRNA-448, 506, 4316, and 4478 analysis for non-invasive diagnosis of lung cancer by Tomasz Powrózek( )

1 edition published in 2015 in English and held by 2 WorldCat member libraries worldwide

Screening for ALK abnormalities in central nervous system metastases of non-small-cell lung cancer( )

1 edition published in 2017 in English and held by 1 WorldCat member library worldwide

CD80 and CD86 on immature myeloid and plasmacytoid blood dendritic cells in pulmonary sarcoidosis( )

1 edition published in 2005 in English and held by 1 WorldCat member library worldwide

Materiały z XIIth Congress of Polish Society of Clinical and Experimental Immunology, Lublin
BALF level of the monocyte chemoattractant protein-1 (MCP-1) correlates with the percentage of immature myeloid and plasmacytoid blood dendritic cells in pulmonary sarcoidosis( )

1 edition published in 2005 in English and held by 1 WorldCat member library worldwide

Materiały z XIIth Congress of Polish Society of Clinical and Experimental Immunology, Lublin
EGFR gene mutations in patients with adenosquamous lung carcinoma( )

1 edition published in 2014 in English and held by 1 WorldCat member library worldwide

Abstract Aim Adenosquamous (ADSQ) carcinoma accounts for 1-4% of non-small cell lung cancer (NSCLC). The origin of ADSQ carcinoma and its genetic background is not fully understood. Most studies concerning epidermal growth factor receptor (EGFR) mutation status are performed in adenocarcinoma, while there is limited information about the prevalence of this mutation in ADSQ-bearing Caucasian patients and the efficacy of EGFR tyrosine kinase inhibitors. Methods EGFR gene status has been examined in 1000 non-squamous NSCLC patients of Polish origin. Polymerase chain reaction (PCR) followed by DNA fragment length analysis and allele-specific PCR as well as real-time PCR technique were used to estimate EGFR gene status. Complete clinical data were obtained for all examined patients. Results In the group of 1000 non-squamous NSCLC patients, ADSQ was diagnosed in 14 (1.4%) cases. Activating mutations of EGFR were observed in 28.6% (four out of 14) of ADSQ-bearing patients and included deletions of 15 base-pairs in exon 19 in three cases (one man and two women) and substitution of L861Q with coexistence of G719X mutation in one non-smoking male patient. Deletions were diagnosed in two non-smoking patients and one current-smoking female patient (50 pack-years). One non-smoking man with deletion in exon 19 of EGFR gene was successfully treated with gefitinib in first-line therapy. Conclusions EGFR gene mutations in ADSQ carcinoma patients may be more common than previously thought. EGFR mutation testing is appropriate in ADSQ-bearing patients, in which response for molecular-based therapy is predictable
Znaczenie badań spirometrycznych w diagnostyce i monitorowaniu leczenia astmy = Detection of latent tuberculosis infection in BCG vaccinated children by Barbara Maciejewska( )

1 edition published in 2011 in Polish and held by 1 WorldCat member library worldwide

Cyclophosphamide and tucotuzumab (huKS-IL2) following first-line chemotherapy in responding patients with extensive-disease small-cell lung cancer( )

1 edition published in 2015 in English and held by 1 WorldCat member library worldwide

Abstract : The humanized KS-interleukin-2, tucotuzumab (huKS-IL2; EMD 273066), is an EpCAM-specific immunocytokine with reported immunologic activity in combination with cyclophosphamide. This Phase 2, randomized, open-label study compared tucotuzumab/cyclophosphamide, administered as maintenance, with best supportive care (BSC) in patients with extensive-disease small-cell lung cancer (ED-SCLC) who responded to first-line platinum-based chemotherapy with/without prophylactic cranial irradiation (PCI). Patients received cyclophosphamide (300 mg/m 2, Day 1 of every 3-week cycle), followed by tucotuzumab (1.5 mg/m 2, Days 2-4) until disease progression. The primary endpoint was 6-month progression-free survival (PFS); the secondary objectives included overall survival (OS), treatment response, and safety. The 6-month PFS rate was lower in the tucotuzumab/cyclophosphamide group (n =64) than in the BSC group (n =44): 6.4 versus 12.2% [hazard ratio (HR): 0.98; 80% confidence interval (CI): 0.74-1.31]. HRs for PFS, time to progression, and OS indicated a similar risk of disease progression and death in both groups and best overall responses were generally comparable. For patients with previous PCI (n =26), there was a nonsignificant trend toward prolonged median PFS (1.7 vs. 1.5 months; HR: 0.60; 80% CI: 0.33-1.11) and OS (21.5 vs. 14.3 months; HR: 0.58; 80% CI: 0.31-1.05) in the tucotuzumab/cyclophosphamide group. Adverse events were more frequent with tucotuzumab/cyclophosphamide (92.2%) than with BSC (47.7%). Tucotuzumab/cyclophosphamide was well tolerated in ED-SCLC patients, but did not show PFS or OS benefits compared with BSC. The observed trend toward prolonged PFS and OS in the subgroup of patients receiving previous PCI may support further confirmation in a larger population
Toruń 2010 : na co wydajemy miejskie pieniądze?( Book )

1 edition published in 2010 in Polish and held by 1 WorldCat member library worldwide

Screening for gene mutations in central nervous system metastases of non-small-cell lung cancer( )

1 edition published in 2018 in English and held by 1 WorldCat member library worldwide

Toruń 2009 : na co wydajemy miejskie pieniądze? by Małgorzata Litwin( Book )

1 edition published in 2009 in Polish and held by 1 WorldCat member library worldwide

Age influence on hypersensitivity pneumonitis induced in mice by exposure to Pantoea agglomerans( )

1 edition published in 2013 in English and held by 1 WorldCat member library worldwide

<Title>Abstract</title>Hypersensitivity pneumonitis (HP) represents the immunologically mediated lung disease induced by repeated inhalations of a wide variety of certain finely dispersed organic antigens. In susceptible subjects, these inhalations provoke a hypersensitivity reaction characterized by intense inflammation of the terminal bronchioles, the interstitium and the alveolar tree. The inflammation often organizes into granulomas and may progress to pulmonary fibrosis. Our previous work indicated that cell extract of gram-negative bacteria<italic>Pantoea agglomerans</italic>(SE-PA) causes, in young C57BL/6J mice, pulmonary changes that are very similar to the clinical manifestations of HP in men. The purpose of presented studies was to describe the response of mice immune system while exposed to SE-PA. Particular attention was paid to examine the age influence on SE-PA induced inflammation and fibrosis in lung tissue. We used 3- and 18-month-old C57BL/6J mice. Lung samples were collected from untreated mice and animals exposed to harmful agent for 7 and 28 days. HP development was monitored by histological and biochemical evaluation. Using ELISA tests, we examined concentration of pro- and anti-inflammatory cytokines in lung homogenates. Our study demonstrated again that SE-PA provokes in mice changes typical for the clinical picture of HP, and that successive stages of disease (acute, subacute and chronic) might be obtained by modulation of time exposure. Furthermore, we found that animals' age at the time of sensitization influences the nature of observed changes (cytokine expression pattern) and the final outcome (reaction intensity and scale of fibrosis)
Evaluation of dendritic cells in malignant pleural effusion of non-small cell lung cancer patients in comparison to reference group( )

1 edition published in 2005 in English and held by 1 WorldCat member library worldwide

Materiały z XIIth Congress of Polish Society of Clinical and Experimental Immunology, Lublin
 
moreShow More Titles
fewerShow Fewer Titles
Audience Level
0
Audience Level
1
  Kids General Special  
Audience level: 0.96 (from 0.88 for Age influe ... to 0.99 for Palenie ty ...)

WorldCat IdentitiesRelated Identities
Languages
English (16)

Polish (4)